Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402]

The authors regret that due to a typing error the title of the manuscripts reported the wrong term “Naringerin” instead of “Naringenin”, which is the correct term used throughout the manuscript.

The authors would like to apologise for any inconvenience caused.